Gizem Rizki

Even the most validated models fail without high-quality cells. Limited access to primary cells and batch-to-batch variability pose major challenges for reproducibility and scalability. This workshop examines sourcing strategies, IPSC applications, and centralized approaches to ensure sufficient, consistent cells for 3D tissue models. Learn how companies streamline cell acquisition and address patient heterogeneity for more predictive complex in vitro systems.

• Centralizing primary cell sourcing to reduce variability and achieve consistent readouts
• Evaluating iPSC benefits and limitations to expand cell availability and accelerate iPSC development timelines
• Streamlining cell acquisition from clinics to minimize human error and variability in cell quality
• Addressing low primary cell availability to capture patient heterogeneity and improve model predictability